Gene expression biomarkers of response to citalopram treatment in major depressive disorder

Translational Psychiatry

Volumn 1, Issue , 2011, Pages

  Mamdani, F ^a   Berlim, M T ^a   Beaulieu, M M ^a   Labbe, A ^c   Merette, C ^b   Turecki, G ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; INTERFERON REGULATORY FACTOR 7;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; GENOTYPE; HUMAN; MAJOR DEPRESSION; METABOLISM; METHODOLOGY; PHARMACOGENETICS; PREFRONTAL CORTEX; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENOTYPE; HUMANS; INTERFERON REGULATORY FACTOR-7; PHARMACOGENETICS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 79959550112     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2011.12     Document Type: Review

References (67)

1. Murray CJL, Lopez AD. The Global Burden of Disease. WHO: Geneva, 1998.
2. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: acuteand continuation treatment of majordepressive disorder. WorldJ Biol Psychiatry 2002; 3: 5-43.
3. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet2001; 2: 9-39. (Pubitemid 35264999)
4. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for betterdrug therapy. AnnuRev Pharmacol Toxicol 2001; 41:101-121. (Pubitemid 32385884)
5. Nelson JC. Managing treatment-resistant major depression. J Clin Psychiatry 2003; 64(Suppl1): 5-12. (Pubitemid 36206106)
6. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L etal. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
7. Kemp AH, Gordon E, Rush AJ, Williams LM. Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. CNS Spectr 2008; 13:1066-1086.
8. Akiskal HS, Bourgeois ML, Angst J, Post R, Moller H, Hirschfeld R. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J AffectDisord 2000; 59(Suppl1): S5-S30. (Pubitemid 32164448)
9. Franchini L, Serretti A, Gasperini M, Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998; 32: 255-259. (Pubitemid 28410114)
10. Serretti A, Franchini L, Gasperini M, Rampoldi R, Smeraldi E. Mode of inheritance in mood disorderfamilies according to fluvoxamine response. Acta Psychiatr Scand 1998; 98:443-450. (Pubitemid 28566294)
11. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge Retal.Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369. (Pubitemid 36957839)
12. Nagasaki K, Miki Y. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer 2008; 15:117-120.
13. Zembutsu H, Suzuki Y, Sasaki A, Tsunoda T, Okazaki M, Yoshimoto M et al. Predicting response to docetaxel neoadjuvant chemotherapy for advanced breast cancers through genome-wide gene expression profiling. Int J Oncol 2009; 34: 361-370.
14. Schetter AJ, Leung SY, SohnJJ, Zanetti KA, Bowman ED,Yanaihara N et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436. (Pubitemid 351185951)
15. Kittleson MM, Minhas KM, Irizarry RA, Ye SQ, Edness G, Breton E et al. Gene expression in giant cell myocarditis: altered expression of immune response genes. Int J Cardiol2005; 102: 333-340. (Pubitemid 40854052)
16. Marziliano N, Grasso M, Pilotto A, Porcu E, Tagliani M, Disabella E et al. Transcriptomic and proteomic analysis in the cardiovascular setting: unravelling the disease? J Cardiovasc Med (Hagerstown) 2009; 10: 433-442.
17. Matkovich SJ, Van Booven DJ, Youker KA, Torre-Amione G, Diwan A, Eschenbacher WH et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009; 119:1263-1271.
18. Kalman J, Palotas A, Juhasz A, Rimanoczy A, Hugyecz M, Kovacs Z et al. Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression-evolution of antidepressants and the role of the "neuro-immune" system. Neurochem Res 2005; 30:1429-1438. (Pubitemid 41784479)
19. Palotas A,Puskas LG, Kitajka K, Palotas M,Molnar J, Pakaski M et al.Alteredresponseto mirtazapine on gene expression profile of lymphocytes from Alzheimer's patients. Eur J Pharmacol 2004; 497: 247-254. (Pubitemid 39164890)
20. Palotas A, Puskas LG, Kitajka K, Palotas M, Molnar J, Pakaski M et al. The effect of citalopram on gene expression profile of Alzheimer lymphocytes. Neurochem Res 2004; 29: 1563-1570. (Pubitemid 38860239)
21. Belzeaux R, Formisano-Treziny C, Loundou A, Boyer L, Gabert J, Samuelian JC et al. Clinical variations modulate patterns of gene expression and define blood biomarkers in major depression. J Psychiatr Res 2010; 44:1205-1213.
22. Iga J, Ueno S, Yamauchi K, Numata S, Kinouchi S, Tayoshi-Shibuya S et al. Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Prog Neuropsychophamacol Biol Psychiatry 2007; 31: 628-632. (Pubitemid 46467041)
23. Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S et al. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 658-663. (Pubitemid 46476822)
24. McClintick JN, Edenberg HJ. Effects of filtering by present call on analysis of microarray experiments. BMC Bioinformatics 2006; 7: 49.
25. Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry 2002; 47: 262-266. (Pubitemid 34614684)
26. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
27. Hercher C, Turecki G, Mechawar N. Through the looking glass: examining neuroanatomical evidence for cellular alterations in major depression. J Psychiatr Res 2009; 43: 947-961.
28. Paun A, Pitha PM. The IRF family, revisited. Biochimie 2007; 89: 744-753. (Pubitemid 47001634)
29. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005; 434: 772-777. (Pubitemid 44739521)
30. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 2000; 275: 31805-31812.
31. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999; 461:199-233.
32. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9: 46-56. (Pubitemid 350295688)
33. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychophamacol Biol Psychiatry 1995; 19:11-38.
34. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999; 461: 25-46.
35. Kim YK, Na KS, Shin KH, Jung HY, Choi SH, Kim JB. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1044-1053.
36. Maes M, Song C, Lin A, De JR, Van GA, Kenis G et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine 1998; 10: 313-318. (Pubitemid 28227076)
37. Qin L, Wu X, Block ML, Liu Y, Breese GR, Hong JS et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007; 55: 453-462. (Pubitemid 46383175)
38. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Increased CD56+ natural killer cells and related cytokines in major depression. Clin Immunol Immunopathol 1996; 78: 83-85. (Pubitemid 26078315)
39. Kent S, Bluthe RM, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13: 24-28.
40. Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl JMed 1999; 340:1370.
41. McDonald EM, Mann AH, Thomas HC. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers. Lancet 1987; 2:1175-1178.
42. Maes M, Meltzer HY, Scharpe S, Cooreman W, Uyttenbroeck W, Suy E et al. Psychomotor retardation, anorexia, weight loss, sleep disturbances, and loss of energy: psychopathological correlates of hyperhaptoglobinemia during major depression. Psychiatry Res 1993; 47: 229-241. (Pubitemid 23190382)
43. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 201-217. (Pubitemid 40202906)
44. Yirmiya R, Weidenfeld J, Pollak Y, Morag M, Morag A, Avitsur R et al. Cytokines, "depression due to a general medical condition," and antidepressant drugs. Adv Exp Med Biol 1999; 461: 283-316.
45. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med2003; 35: 2-11. (Pubitemid 36356868)
46. Cassidy EM, Manning D, Byrne S, Bolger E, Murray F, Sharifi N et al. Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J Psychopharmacol 2002; 16: 230-234. (Pubitemid 34983078)
47. Shimizu H, Ohtani K, Sato N, Nagamine T, MoriM. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. EndocrJ 1995; 42: 551-556.
48. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009; 34: 4-20.
49. SpijkerS,VanZantenJS, De JS, PenninxBW,van DR,Zitman FG et al.Stimulatedgene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010; 68: 179-186.
50. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001; 58: 445-452. (Pubitemid 32411324)
51. Hu VW, Frank BC, Heine S, Lee NH, Quackenbush J. Gene expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in severity of autism reveals differential regulation of neurologically relevant genes. BMC Genomics2006; 7:118.
52. Hu VW, Nguyen A, Kim KS, Steinberg ME, Sarachana T, Scully MA et al. Gene expression profiling of lymphoblasts from autistic and nonaffected sib pairs: altered pathways in neuronal development and steroid biosynthesis. PLoS One 2009; 4: e5775.
53. Hu VW, SarachanaT, Kim KS, Nguyen A, Kulkarni S, Steinberg ME et al. Gene expression profiling differentiates autism case-controls and phenotypic variants of autism spectrum disorders: evidence forcircadian rhythm dysfunction in severe autism. Autism Res 2009; 2: 78-97.
54. Nishimura Y, Martin CL, Vazquez-Lopez A, Spence SJ, Alvarez-Retuerto AI, Sigman M et al. Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet 2007; 16:1682-1698. (Pubitemid 47241828)
55. Talebizadeh Z, Butler MG, Theodoro MF. Feasibility and relevance of examining lymphoblastoid cell lines to study role of microRNAs in autism. Autism Res 2008; 1: 240-250.
56. Chagnon YC, Roy MA, Bureau A, Merette C, Maziade M. Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes. Schizophr Res 2008; 100: 281-290.
57. Suzuki K, Nakamura K, Iwata Y, Sekine Y, Kawai M, Sugihara G et al. Decreased expression of reelin receptor VLDLR in peripheral lymphocytes of drug-naive schizophrenic patients. Schizophr Res 2008; 98:148-156. (Pubitemid 350235901)
58. de LJ,Susce MT,Johnson M, Hardin M, MawL,ShaoAet al. DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectr 2009; 14:19-34.
59. Domenici E, Wille DR, Tozzi F, Prokopenko I, Miller S, McKeown A et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: e9166.
60. Fisar Z, Kalisova L, Paclt I, Anders M, Vevera J. Platelet serotonin uptake in drug-naive depressive patients before and aftertreatmentwith citalopram. Psychiatry Res 2008; 161: 185-194.
61. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009; 27:1382-1387.
62. Swen JJ, Huizinga TW, Gelderblom H, de Vries EG, Assendelft WJ, Kirchheiner J et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007; 4: e209.
63. Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, MaierW et al. Adverse reactionsto antidepressants. Br J Psychiatry 2009; 195: 202-210.
64. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol1995; 10(Suppl1): 15-21.
65. Bezchlibnyk-Butler K, Aleksic I, Kennedy SH. Citalopram-a review of pharmacological and clinical effects. J Psychiatry Neurosci 2000; 25: 241-254. (Pubitemid 30641001)
66. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985; 28: 553-557. (Pubitemid 15030781)
67. Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996; 18:111-117. (Pubitemid 26104615)